| P50 | author | Klaus F. Ley | Q89016809 |
| P2093 | author name string | Kouji Kobiyama | |
| | Yanal Ghosheh | |
| | Payel Roy | |
| | Amal J Ali | |
| P2860 | cites work | Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation | Q24303660 |
| | Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis | Q26801433 |
| | Artery Tertiary Lymphoid Organs: Powerhouses of Atherosclerosis Immunity | Q28072367 |
| | Autoreactive HSP60 epitope-specific T-cells in early human atherosclerotic lesions | Q28710388 |
| | Artery Tertiary Lymphoid Organs Control Multilayered Territorialized Atherosclerosis B-Cell Responses in Aged ApoE-/- Mice | Q30276940 |
| | B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis | Q30279171 |
| | Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. | Q30359230 |
| | Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease | Q31135767 |
| | Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice | Q31807203 |
| | Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis | Q33207408 |
| | Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study | Q33663533 |
| | T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses | Q33819043 |
| | A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. | Q34047773 |
| | Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine | Q34238712 |
| | IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis. | Q34364890 |
| | Antibodies against heat shock proteins in environmental stresses and diseases: friend or foe? | Q34446467 |
| | A cholesterol-lowering VLP vaccine that targets PCSK9 | Q34496015 |
| | Genetics of coronary artery disease: discovery, biology and clinical translation | Q34553141 |
| | Characterization of resident B cells of vascular walls in human atherosclerotic patients. | Q34955086 |
| | Decreased regulatory T cells in vulnerable atherosclerotic lesions: imbalance between pro- and anti-inflammatory cells in atherosclerosis | Q35034094 |
| | Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia | Q35133174 |
| | T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse | Q35213550 |
| | Heat shock protein 60 and immune inflammatory responses in atherosclerosis | Q35540113 |
| | Type 1 diabetes immunotherapy using polyclonal regulatory T cells | Q36509805 |
| | Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges | Q36968971 |
| | A systems biology framework identifies molecular underpinnings of coronary heart disease | Q37119481 |
| | High Serum Immunoglobulin G and M Levels Predict Freedom From Adverse Cardiovascular Events in Hypertension: A Nested Case-Control Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial | Q37149945 |
| | Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines | Q60746676 |
| | Subcutaneous immunization with heat shock protein-65 reduces atherosclerosis in Apoe−/− mice | Q60948409 |
| | Patients With Acute Coronary Syndrome Show Oligoclonal T-Cell Recruitment Within Unstable Plaque | Q61848544 |
| | Low-Density Lipoprotein-Reactive T Cells Regulate Plasma Cholesterol Levels and Development of Atherosclerosis in Humanized Hypercholesterolemic Mice. | Q64915291 |
| | Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis | Q72209255 |
| | Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events | Q79533802 |
| | Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis | Q79711302 |
| | Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression | Q80417831 |
| | Humoral immune response against defined oxidized low-density lipoprotein antigens reflects structure and disease activity of carotid plaques | Q81652647 |
| | Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis | Q82956532 |
| | Toll-like receptor blocker slows beta cell death in type 1 diabetes | Q83408117 |
| | Oral administration of Lactococcus lactis delivered heat shock protein 65 attenuates atherosclerosis in low-density lipoprotein receptor-deficient mice | Q83880274 |
| | Activation of inflammatory cells and cytokines by peptide epitopes in vitro: a simple in-vitro screening assay for prioritizing them for in-vivo studies | Q86095801 |
| | Adventitial macrophage and lymphocyte accumulation accompanying early stages of human coronary atherogenesis | Q87566839 |
| | Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up | Q87620046 |
| | Production of a plant-derived immunogenic protein targeting ApoB100 and CETP: toward a plant-based atherosclerosis vaccine | Q87629622 |
| | Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system | Q91857565 |
| | B Cell Fcγ Receptor IIb Modulates Atherosclerosis in Male and Female Mice by Controlling Adaptive Germinal Center and Innate B-1-Cell Responses | Q92045287 |
| | Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics | Q92052807 |
| | Germinal Center-Derived Antibodies Promote Atherosclerosis Plaque Size and Stability | Q92508225 |
| | Immune and inflammatory mechanisms of atherosclerosis (*) | Q37325024 |
| | Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100. | Q37415733 |
| | The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants. | Q37625241 |
| | CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines | Q37990213 |
| | Engineering lactococci and lactobacilli for human health | Q38121295 |
| | Transgenic plants: a 5-year update on oral antipathogen vaccine development | Q38243438 |
| | Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). | Q38413454 |
| | Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | Q38606033 |
| | Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis | Q38958215 |
| | The Two Faces of Interleukin-17A in Atherosclerosis | Q39052489 |
| | The safety and immunogenicity of a CETP vaccine in healthy adults | Q40574796 |
| | Low Levels of Apolipoprotein B-100 Autoantibodies Are Associated With Increased Risk of Coronary Events | Q40886797 |
| | Mycobacterial heat shock protein 65 (mbHSP65)-induced atherosclerosis: Preventive oral tolerization and definition of atheroprotective and atherogenic mbHSP65 peptides. | Q41076906 |
| | CCR5+T-bet+FoxP3+ Effector CD4 T Cells Drive Atherosclerosis | Q41576199 |
| | Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial | Q42504585 |
| | Effect of immunization against ox-LDL with two different antigens on formation and development of atherosclerosis | Q42970733 |
| | Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices | Q43179678 |
| | Atherosclerosis-Driven Treg Plasticity Results in Formation of a Dysfunctional Subset of Plastic IFNγ+ Th1/Tregs. | Q43273026 |
| | Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis | Q43550562 |
| | Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice | Q43633700 |
| | Immunoglobulin M Type of Autoantibodies to Oxidized Low-Density Lipoprotein Has an Inverse Relation to Carotid Artery Atherosclerosis | Q44608860 |
| | Circulating CD40+ and CD86+ B cell subsets demonstrate opposing associations with risk of stroke. | Q45996735 |
| | Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. | Q46095021 |
| | PCSK9 Inhibitors: Economics and Policy. | Q46248321 |
| | B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions | Q46365271 |
| | Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies | Q46376396 |
| | Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells | Q46473311 |
| | The Th17/Treg imbalance in patients with acute coronary syndrome | Q46737661 |
| | Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice | Q46804215 |
| | Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis | Q47788311 |
| | Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus. | Q49072554 |
| | Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association | Q49546493 |
| | Atherosclerosis Is an Inflammatory Disease which Lacks a Common Anti-inflammatory Therapy: How Human Genetics Can Help to This Issue. A Narrative Review. | Q50318400 |
| | The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. | Q50931633 |
| | Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice. | Q51760069 |
| | Regulatory CD4+ T Cells Recognize MHC-II-Restricted Peptide Epitopes of Apolipoprotein B. | Q52626860 |
| | Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis. | Q52726244 |
| | Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. | Q53153760 |
| | Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. | Q53524929 |
| | The opposite-direction modulation of CD4+CD25+ Tregs and T helper 1 cells in acute coronary syndromes. | Q53551964 |
| | Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. | Q53591929 |
| | Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. | Q54375886 |
| | The Contribution of Autoantibodies to Inflammatory Cardiovascular Pathology. | Q55318081 |
| | Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes | Q56901831 |
| | Natural regulatory T cells control the development of atherosclerosis in mice | Q58149268 |
| | Antigen-Driven Evolution of B Lymphocytes in Coronary Atherosclerotic Plaques | Q58228906 |
| | Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial | Q58732372 |
| P577 | publication date | 2020-01-18 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Opportunities for an atherosclerosis vaccine: From mice to humans | |